Prevalence of early discontinuation and associated factors among a retrospective cohort of etonogestrel contraceptive implant users

Abstract Purpose: To characterise the frequency of and predictors of contraceptive implant discontinuation within 12 months of insertion in our clinical setting. Materials and methods: This retrospective cohort study included women receiving the etonogestrel contraceptive implant at our hospital between May 2007 and May 2012. We abstracted data from charts including implant removal date, bleeding complaints, reproductive and demographic characteristics, prior contraceptive use, tobacco use and implant insertion timing. Our primary outcome was implant discontinuation within 12 months following insertion. SAS 9.4 (SAS Institute Inc., Cary, NC, USA) was used to generate frequencies, bivariate analyses and multivariate logistic regression models. Results: Implant discontinuation was documented in 16% of implant users prior to 12 months (89/544). Women with documented bleeding complaints in the medical record were more likely to discontinue within 12 months (OR: 4.36, CI: 2.71, 7.00). No other demographic or clinical characteristics were associated with premature discontinuation. Having less than two prior pregnancies and tobacco use were associated with documented bleeding complaints. Conclusions: Discontinuation of the implant is associated with bleeding complaints. Women with lower parity and tobacco users may be more likely to experience bleeding or to find it intolerable.

[1]  J. Peipert,et al.  Differences in Contraceptive Discontinuation Among Black and White Women: Evidence from the Contraceptive CHOICE Project. , 2018, Journal of women's health.

[2]  Jay Lin,et al.  Twelve-month discontinuation rates of levonorgestrel intrauterine system 13.5 mg and subdermal etonogestrel implant in women aged 18-44: A retrospective claims database analysis. , 2018, Contraception.

[3]  Kathy Tomaszewski,et al.  Incidence of Discontinuation of Long-Acting Reversible Contraception among Adolescent and Young Adult Women Served by an Urban Primary Care Clinic. , 2017, Journal of pediatric and adolescent gynecology.

[4]  M. Y. Hou,et al.  Combined oral contraceptive treatment for bleeding complaints with the etonogestrel contraceptive implant: a randomised controlled trial , 2016, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[5]  B. Kaneshiro,et al.  Therapeutic Options for Unscheduled Bleeding Associated with Long-Acting Reversible Contraception. , 2015, Obstetrics and gynecology clinics of North America.

[6]  Moazzam Ali,et al.  A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls. , 2015, Human reproduction.

[7]  J. Sheeder,et al.  Short-Term Treatment of Bothersome Bleeding for Etonogestrel Implant Users Using a 14-Day Oral Contraceptive Pill Regimen: A Randomized Controlled Trial , 2015, Obstetrics and gynecology.

[8]  C. Raker,et al.  The effect of immediate postpartum compared to delayed postpartum and interval etonogestrel contraceptive implant insertion on removal rates for bleeding. , 2014, Contraception.

[9]  L. Bahamondes,et al.  A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives. , 2014, Human reproduction.

[10]  B. Grimm,et al.  Continuation rates of the subdermal contraceptive Implanon® and associated influencing factors , 2014, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[11]  V. Newton,et al.  "I think it depends on the body, with mine it didn't work": explaining young women's contraceptive implant removal. , 2013, Contraception.

[12]  Petra M. Casey,et al.  Association of body mass index with removal of etonogestrel subdermal implant. , 2013, Contraception.

[13]  P. Inki,et al.  Acceptability of the levonorgestrel releasing-intrauterine system and etonogestrel implant: One-year results of an observational study , 2012, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[14]  L. Ikeako,et al.  The discontinuation rate and reasons for discontinuation of implanon at the family planning clinic of University of Nigeria Teaching Hospital (UNTH) Enugu, Nigeria. , 2011, Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria.

[15]  R. Pittrof,et al.  Counselling styles and their effect on subdermal contraceptive implant continuation rates , 2011, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[16]  Petra M. Casey,et al.  Bleeding related to etonogestrel subdermal implant in a US population. , 2011, Contraception.

[17]  J. Lucke,et al.  Continuation rates and reasons for removal among Implanon users accessing two family planning clinics in Queensland, Australia. , 2009, Contraception.

[18]  P. Darney,et al.  Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. , 2009, Fertility and sterility.

[19]  C. Westhoff,et al.  Smoking and oral contraceptive continuation. , 2007, Contraception.

[20]  O. Graesslin,et al.  The contraceptive efficacy of Implanon®: A review of clinical trials and marketing experience , 2008, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[21]  I. Fraser,et al.  The effects of Implanon® on menstrual bleeding patterns , 2008, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[22]  A. Glasier,et al.  Continuation rates of Implanon in the UK: data from an observational study in a clinical setting. , 2006, Contraception.